OncoLink at ASCO 1996: Monday, May 20 | Oncolink

Oncolink Features

Find My Cancer Drug

Advances in Supportive Care Offer New Opportunities for Oncology Patients and Clinicians Philadelphia, PA, May 20, 1996 -- Research presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) provided insight into new solutions for maximizing the quality of cancer care. The cost of cancer care is rising...
American Society of Clinical Oncology Announces Research Awards Philadelphia, PA, May 20, 1996 -- James O. Armitage, M.D., professor and chairman, Department of Internal Medicine, University of Nebraska Medical Center, today assumed the presidency of the American Society of Clinical Oncology (ASCO) during...
American Society of Clinical Oncology Announces Research Awards Henry T. Lynch, M.D., professor and chairman, Department of Preventive medicine and Public Heath, and Director, Creighton Cancer Center, Creighton University (Omaha, NE), presented a study of 14 families with hereditary breast-ovarian cancer...
Combined Modality Therapy Shows Improvements in Survival for Certain Cancer Patients Philadelphia, PA, May 20, 1996 -- Important new data regarding the use of combined modality therapy were reported today at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Combined modality therapy refers to the...
Interferon Plus Chemotherapy Is Better Than Chemotherapy Alone In Renal Cell Cancer Seppo Pyrhönen, M.D., senior physician, chief, Outpatient Chemotherapy Unit, Helsinki University Central Hospital (Helsinki, Finland), presented the results of a multicenter trial which compared the effects of combination therapy with...
Interferon Plus Interleukin-2 Is The Optimal Treatment To Induce Responses In Metastatic Renal Cell Cancer Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in...
James O. Armitage, M.D., Assumes ASCO Presidency Philadelphia, PA, May 20, 1996 -- James O. Armitage, M.D., professor and chairman, Department of Internal Medicine, University of Nebraska Medical Center, today assumed the presidency of the American Society of Clinical Oncology (ASCO) during...
John H. Glick, MD Gives Presidential Address Philadelphia, PA , May 20, 1996 John H. Glick, MD, President of ASCO (1995-1996) and Director, University of Pennsylvania Cancer Center, gave his Presidential Address today at the 32nd Annual Meeting of the American Society of Clinical Oncology...
Long-Term Survival Following Immunization with BEC2 Plus BCG after Initial Therapy for Small Cell Lung Cancer Sylvie Négrier, M.D., associate professor, Department of Medical Oncology, Centre Leon Berard (Lyon, France), presented the results of another study demonstrating the effects of interferon, as well as another cytokine, interleukin-2, in...
Randomized Trial Of 2 Vs. 5 Years Of Adjuvant Tamoxifen In Postmenopausal Women With Early-Stage Breast Cancer Lars E. Rutqvist, M.D., Ph.D., director, Oncology Center, Karolinska Hospital (Stockholm, Sweden), presented the results of a study which aimed to determine the optimal duration of tamoxifen treatment for early-stage breast cancer patients. ...
Research Presented Helps to Define Best Use and Timing of Bone Marrow Transplantation Philadelphia, PA, May 18, 1996-- Exciting new research that better defines the role and timing of bone marrow transplantation was presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Bone marrow transplantation...